Clinical trials: Genital Neoplasms
Prostate Cancer
Evaluating E7389 in Patients With Hormone Refractory Prostate Cancer With Advanced and/or Metastatic Disease Stratified by Prior Chemotherapy
This is a multi-centre, phase II, open-label, two-stage design, single-arm study in patients with hormone-refractory prostate cancer (HRPC) with advanced (rising PSA) and/or metastatic disease and who have had prior anti-androgen…
- Trial name
- NCT00278993
- Testing
- E7389
- Where
- 18 sites in United States
- Volunteers
- 108 people
- Sponsor
- Eisai Inc.
Prostate Cancer
Samarium-153 With Neoadjuvant Hormonal and Radiation Therapy for Locally Advanced Prostate Cancer
The purpose of this study is to determine the safety and effectiveness of Samarium-153 when given in combination with hormonal and external beam radiation therapy in men with high risk prostate cancer.
- Trial name
- NCT00328614
- Testing
- Samarium-153, Total Androgen Suppression (TAS) with Bicalutamide, Total androgen suppression (TAS) with Goserelin Acetate
- Where
- United States
- Volunteers
- 32 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
Hormone-Resistant Prostate Cancer, Prostate Adenocarcinoma
Tivantinib in Treating Patients With Metastatic Prostate Cancer
This randomized phase II trial studies how well tivantinib works compared to placebo in treating patients with metastatic prostate cancer.
- Conditions
- Hormone-Resistant Prostate Cancer, Prostate Adenocarcinoma, Recurrent Prostate Carcinoma, Stage IV Prostate Cancer
- Trial name
- NCT01519414
- Testing
- Laboratory Biomarker Analysis, Tivantinib
- Where
- 20 sites in United States
- Volunteers
- 78 people
- Sponsor
- National Cancer Institute (NCI)
Prostate Cancer, Metastatic (Spread to Other Areas of the Body)
BKM120 in Metastatic Castration-resistant Prostate Cancer
The purpose of this study is to evaluate the effects of the study drug, BKM120. The study drug, BKM120, is an inhibitor of a protein called phosphatidyl inositol-3-kinase (PI3K).
- Trial name
- NCT01385293
- Testing
- BKM120
- Where
- 3 sites in United States
- Volunteers
- 30 people
- Sponsor
- Andrew J. Armstrong, MD
Uterine Cervical Neoplasms
Conducting Outreach to Improve Cervical Cancer Screening Rates Among Underscreened Patients
The purpose of this project is to determine whether outreach to HIV-negative patients who are overdue for a Pap smear at a New England urban community health center can increase cervical cancer screening rates.
- Trial name
- NCT02427399
- Testing
- Letter and informational sheet, Email, Phone
- Volunteers
- 1,100 people, healthy volunteers welcome
- Sponsor
- Fenway Community Health
Prostate Cancer
Vaccine Therapy With PROSTVAC/TRICOM and Flutamide Versus Flutamide Alone to Treat Prostate Cancer
Background: Flutamide is an approved drug for prostate cancer that blocks the effects of testosterone on prostate cancer cells and may slow the progression of the disease.
- Trial name
- NCT00450463
- Testing
- Sargramostim (GM-CSF, Leukine), Flutamide (Eulexin), PROSTVAC-F/ TRICOM
- Where
- 3 sites in United States
- Volunteers
- 64 people
- Sponsor
- National Cancer Institute (NCI)
Uterine Fibroid, Arteriovenous Malformations
An Observational Study of Radial Access Embolization Procedures Using HydroPearl Microspheres
This registry study is designed to collect data on the procedural success and complication rates in real-world patients undergoing HydroPearl embolization procedures via radial access.
- Conditions
- Uterine Fibroid, Arteriovenous Malformations, Hypervascular Tumors, Benign Prostatic Hyperplasia
- Trial name
- RAVI Registry (NCT04272216)
- Testing
- Treatment with HydroPearl via radial access
- Where
- 6 sites in United States
- Volunteers
- 99 people
- Sponsor
- Terumo Medical Corporation
Prostate Cancer
A Long-term Extension Study Evaluating a One-Month Dosing Regimen of Degarelix in Prostate Cancer Requiring Androgen Ablation Therapy
Participants who completed the FE200486 CS21 study (NCT00295750) could enter the FE200486 CS21A study. The study continued until all non-discontinued participants had received treatment for at least 5 years.
- Trial name
- NCT00451958
- Testing
- Degarelix 80 mg / Degarelix 80 mg, Degarelix 160 mg / Degarelix 160 mg, Leuprolide 7.5 mg / Degarelix 80 mg
- Where
- 69 sites in United States, Canada and 10 more
- Volunteers
- 386 people
- Sponsor
- Ferring Pharmaceuticals
Carcinoma of the Cervix, Carcinoma or Carcinosarcoma of the Uterus
Suitability of DCE-MRI for Detection of Vascular Changes After VBT
This is a pilot study of DCE MR imaging to detect vascular changes in the vagina during and after radiotherapy n patients receiving adjuvant brachytherapyfor cervical or endometrial cancer.
- Trial name
- NCT01991808
- Testing
- Radiotherapy
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- Abramson Cancer Center at Penn Medicine
Metastatic Prostate Cancer, Non-metastatic Prostate Cancer
Neo-DAB: Darolutamide and Abemaciclib in Prostate Cancer
This research study is trying to determine the safety and efficacy of the combination of two oral drugs, abemaciclib and darolutamide, with androgen deprivation therapy (ADT) in the treatment of metastatic, non-metastatic, and…
- Conditions
- Metastatic Prostate Cancer, Non-metastatic Prostate Cancer, Prostate Cancer
- Trial name
- NCT05617885
- Testing
- Darolutamide, Abemaciclib, GNRH-A Leuprolide Acetate
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- Praful Ravi, MB BCHir, MRCP
Prostate Cancer
AMG 162 in the Treatment of Bone Loss in Subjects Undergoing Androgen-Deprivation Therapy for Non-metastatic Prostate Cancer
This study will evaluate AMG 162 in the treatment of bone loss in subjects undergoing Androgen-Deprivation Therapy for Non-metastatic Prostate Cancer.
- Trial name
- NCT00089674
- Testing
- AMG 162
- Volunteers
- 1,468 people
- Sponsor
- Amgen
Prostate Cancer
Safety Study of Continued Enzalutamide Treatment In Prostate Cancer Patients
The purpose of this study is to determine if continued treatment with Enzalutamide is effective in patients with metastatic prostate cancer.
- Trial name
- PLATO (NCT01995513)
- Testing
- Enzalutamide, Abiraterone, Prednisone
- Where
- 95 sites in United States, Australia and 9 more
- Volunteers
- 509 people
- Sponsor
- Pfizer
Prostate Cancer
A Study of Definitive Therapy to Treat Prostate Cancer After Prostatectomy
To assess the safety of treating men with oligometastatic prostate cancer with the following therapy: (1st) Systemic chemo-hormonal therapy with up to 6-months (~24 weeks) of adjuvant androgen deprivation and up to 6 cycles of…
- Trial name
- NCT03043807
- Testing
- Leuprolide Acetate, Docetaxel, Bicalutamide
- Where
- 2 sites in United States
- Volunteers
- 26 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Hormone-resistant Prostate Cancer, Recurrent Prostate Cancer
AZD0530 in Treating Patients With Prostate Cancer That Did Not Respond to Hormone Therapy
This phase II trial is studying how well AZD0530 works in treating patients with prostate cancer that did not respond to hormone therapy.
- Trial name
- NCT00513071
- Testing
- saracatinib, laboratory biomarker analysis
- Where
- United States
- Volunteers
- 28 people
- Sponsor
- National Cancer Institute (NCI)
Cervical Cancer
Acceptability of Human Papillomavirus (HPV) Self-sampling Tools for Cervical Cancer Prevention
The proposed study aims to increase HPV screening behaviors in Jamaican women by examining the acceptability of HPV Deoxyribonucleic Acid (DNA) self-sampling tools, and to determine the most culturally appropriate and effective…
- Trial name
- NCT03613493
- Testing
- HPV self-sampling kit, Culturally-targeted Fear Appeal Message, Fear Appeal Message
- Where
- United States
- Volunteers
- 175 people, healthy volunteers welcome
- Sponsor
- University of Miami
Prostate Cancer
Study to Compare Capsule and Liquid Formulations of Enzalutamide After Single Dose Administration Under Fasting Conditions in Prostate Cancer
Background: Enzalutamide is given to treat metastatic prostate cancer. But it takes 4 pills to deliver the effective dose. This can be difficult for people already taking multiple drugs.
- Trial name
- NCT03478904
- Testing
- Enzalutamide Liquid, Enzalutamide Capsule
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- National Cancer Institute (NCI)
Melanoma, Prostate Cancer
Low Dose Naltrexone for Metastatic Melanoma, Castrate Resistant Prostate Cancer and Renal Cancer
will scientifically evaluate whether Low Dose Naltrexone (LDN) has activity in refractory solid tumors within the context of a phase II clinical study
- Conditions
- Melanoma, Prostate Cancer, Renal Cancer
- Trial name
- NCT01650350
- Testing
- Naltrexone
- Where
- United States
- Volunteers
- 7 people
- Sponsor
- Brown University
Prostate Cancer
68Ga-RM2 for PET/CT of Gastrin Releasing Peptide Receptor (GRPr) Expression in Prostate Cancer
The purpose of this study is to see if a new diagnostic research agent named 68Ga-RM2 can show prostate cancer on a PET/CT scan.
- Trial name
- NCT02559115
- Testing
- 68Ga-RM2 (RM2), PET/CT Scan
- Where
- United States
- Volunteers
- 19 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Brain and Central Nervous System Tumors, Childhood Germ Cell Tumor
Dasatinib, Ifosfamide, Carboplatin, and Etoposide in Treating Young Patients With Metastatic or Recurrent Malignant Solid Tumors
RATIONALE: Dasatinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs in chemotherapy, such as ifosfamide, carboplatin, and etoposide, work in different ways to stop the growth of…
- Conditions
- Brain and Central Nervous System Tumors, Childhood Germ Cell Tumor, Extragonadal Germ Cell Tumor, Kidney Cancer
- Trial name
- NCT00788125
- Testing
- carboplatin, dasatinib, etoposide phosphate
- Where
- United States
- Volunteers
- 7 people
- Sponsor
- City of Hope Medical Center
Metastatic Prostate Cancer, Pain
Non-Randomized Trial Assessing Pain Efficacy With Radium-223 in Symptomatic Metastatic Castration-Resistant Prostate Cancer
The purpose of this study is to find out if Radium-223 is effective in reducing cancer pain within 12 weeks of treatment. In order to see if Radium-223 is effective, the patient's level of pain will be followed throughout the…
- Trial name
- NCT02278055
- Testing
- Radium-223
- Where
- 3 sites in United States
- Volunteers
- 29 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.